Unique Value Proposition

There are 4 million patients dependent on insulin in the EU and US alone. Despite intensive glucose control, the majority of patients on insulin will eventually develop long-term complications. 

The percentage of type 1 diabetes patients in the US suffering from these complications.

 

80% of patients with type 1 diabetes will eventually develop neuropathy

• It is estimated that 4 million people in the U.S. and Europe have type 1 diabetes and about 15,000 American children are diagnosed with type 1 diabetes every year.
• Type 1 diabetes is characterized by the body's inability to produce pro-insulin and consequently both insulin and C-peptide.
• Type 1 and some type 2 diabetic patients have a C-peptide deficiency, which can cause a reduction in microvascular circulation, resulting in progressive damage to the nerves, retina and kidneys.
• C-peptide replacement represents a unique and rational approach to the prevention and treatment of long-term complications of diabetes, such as peripheral neuropathy, autonomic neuropathy, retinopathy, nephropathy.
• Cebix is developing Ersatta^TM, a proprietary disease-modifying C-peptide replacement for the treatment of complications associated with diabetes.
• Ersatta is designed to improve vascular and neuronal health while exhibiting the safety profile consistent with native peptide replacement therapy.
• In addition to type 1 diabetics, another group of insulin-deficient patients, those afflicted with latent autoimmune diabetes in the adult (LADA), could benefit from C-peptide treatment as approximately 50% of these patients will develop peripheral neuropathy. The number of LADA patients in North America and Europe is approximately 2 million.